Tilray Brands (NASDAQ:TLRY) Stock Price Up 1.8% – Here’s Why

Tilray Brands, Inc. (NASDAQ:TLRY) shares rose 1.8% during mid-day trading on Thursday . The company traded as high as $5.71 and last traded at $5.65. Approximately 4,280,655 shares changed hands during trading, a decline of 3% from the average daily volume of 4,410,574 shares. The stock had previously closed at $5.55.

More Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray announced a new premium cannabis launch from its Broken Coast brand, introducing Cherry Ztripez flower and pre-rolls for summer. The rollout supports its premium product strategy and could help revenue and brand momentum. Article Title
• Positive Sentiment: A sector article flagged TLRY as one of the top Canadian marijuana stocks to watch, citing long-term industry potential, international expansion, improving operational efficiency, and possible U.S. cannabis reform as catalysts. Article Title
• Neutral Sentiment: Short-interest data showed no reported short interest change, offering little new trading signal for investors. Article Title
• Negative Sentiment: Recent commentary noted that Tilray’s stock has fallen sharply this year and remains under pressure, reflecting persistent concerns about the company’s fundamentals and the pace of any recovery. Article Title
• Negative Sentiment: Analysts and media coverage continue to emphasize that a meaningful breakout likely depends on U.S. federal cannabis reform, which remains uncertain and limits near-term upside. Article Title

Analysts Set New Price Targets

TLRY has been the topic of a number of recent research reports. Zacks Research raised Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. ATB Cormark Capital Markets decreased their target price on Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating on the stock in a research note on Thursday, April 2nd. TD Cowen decreased their target price on Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Weiss Ratings lowered Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen upgraded Tilray Brands from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Tilray Brands presently has an average rating of “Hold” and an average price target of $11.50.

Tilray Brands Price Performance

The firm has a market capitalization of $658.51 million, a P/E ratio of -0.41 and a beta of 1.94. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.66 and a current ratio of 2.79. The business has a 50 day simple moving average of $6.25 and a two-hundred day simple moving average of $7.97.

Tilray Brands (NASDAQ:TLRY) last announced its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.10). The firm had revenue of $206.73 million for the quarter, compared to the consensus estimate of $201.35 million. Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. During the same quarter last year, the company posted ($0.87) earnings per share. On average, sell-side analysts expect that Tilray Brands, Inc. will post -0.58 EPS for the current fiscal year.

Insider Activity at Tilray Brands

In other news, Director David G. Hopkinson sold 33,556 shares of the stock in a transaction dated Tuesday, April 21st. The stock was sold at an average price of $6.94, for a total transaction of $232,878.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.84% of the company’s stock.

Hedge Funds Weigh In On Tilray Brands

Several institutional investors have recently modified their holdings of the company. Hilton Head Capital Partners LLC bought a new position in shares of Tilray Brands during the 4th quarter valued at about $38,000. Pictet Asset Management Holding SA increased its position in shares of Tilray Brands by 38.9% during the 1st quarter. Pictet Asset Management Holding SA now owns 18,387 shares of the company’s stock valued at $119,000 after purchasing an additional 5,145 shares during the last quarter. Schonfeld Strategic Advisors LLC increased its position in shares of Tilray Brands by 4.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 144,358 shares of the company’s stock valued at $1,304,000 after purchasing an additional 6,182 shares during the last quarter. Baader Bank Aktiengesellschaft increased its position in shares of Tilray Brands by 17.7% during the 1st quarter. Baader Bank Aktiengesellschaft now owns 47,938 shares of the company’s stock valued at $293,000 after purchasing an additional 7,226 shares during the last quarter. Finally, IFP Advisors Inc increased its position in shares of Tilray Brands by 14.3% during the 4th quarter. IFP Advisors Inc now owns 60,318 shares of the company’s stock valued at $545,000 after purchasing an additional 7,541 shares during the last quarter. 9.35% of the stock is currently owned by institutional investors.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.